RYBREVANT® (amivantamab-vmjw)
Pivotal clinical trial publications
CHRYSALIS
PAPILLON
- Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389:2039-2051.
- Zhou C, Tang KJ, Cho BC, et al. Supplementary Appendix for: Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389:2039-2051.
MARIPOSA
- Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
- Cho BC, Lu S, Felip E, et al. Supplementary Appendix for: Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
MARIPOSA-2
- Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
- Passaro A, Wang J, Wang Y, et al. Supplementary Appendix for: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
Plain language summaries of pivotal clinical trials
CHRYSALIS
PAPILLON
MARIPOSA
MARIPOSA-2